A carregar...
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at well tolerated doses. However, primary or, less often, secondary resistance to DAs may be also encountered representing challeng...
Na minha lista:
| Publicado no: | Pituitary |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6957547/ https://ncbi.nlm.nih.gov/pubmed/31522358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-019-00987-3 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|